Hybrigenics is a French biotech company. It is developing its lead drug, inecalcitol, against orphan adult leukaemias and is currently conducting an international Phase II study in acute myeloid leukaemia. The company has a research programme on USP inhibitors and an R&D collaboration with Servier focused on USP inhibitors in oncology.
More Hybrigenics content >Investment summary
Edison Investment Research is terminating coverage on Hybrigenics (ALHYG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
---|---|---|---|---|---|---|
2016A | 2.6 | (3.5) | (4.0) | (11.2) | N/A | N/A |
2017A | 1.9 | (6.8) | (7.3) | (17.7) | N/A | N/A |
2018E | 3.6 | (3.5) | (4.1) | (8.7) | N/A | N/A |
2019E | 2.2 | (3.3) | (4.0) | (7.6) | N/A | N/A |
Content on Hybrigenics
Hybrigenics – Termination of coverage
Healthcare
|
research Termination
|
4 January 2019





Hybrigenics – Fresh funds to expand clinical studies and R&D
Healthcare
|
research Update
|
14 August 2018





Hybrigenics – H117 results released, business on track
Healthcare
|
research Non-client QV
|
14 August 2018





Sector |
---|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
---|---|
Forecast net cash (€m) | 1.5 |
Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
Key management |
|
---|---|
Alain Muňoz | Chairman |
Rémi Delansorne | CEO |
Guillaume Floch | CFO |
You may also be interested in…
- Abliva
- AlzeCure Pharma
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- Cantargia
- Carmat
- Deinove
- Herantis Pharma
- Immunicum
- Immunovia
- IRLAB Therapeutics
- Kiadis Pharma
- MagForce
- Medigene
- MOLOGEN
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- RhoVac
- Ryvu Therapeutics
- Scandion Oncology
- Sequana Medical
- Targovax
- Transgene
- TxCell
- Ultimovacs
- Vivesto
- Xbrane Biopharma